These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 1619569)
1. Discontinuous alterations of platelet structure and function by bound, ionizable verapamil. Retzinger GS; Cohen L J Pharm Sci; 1992 Jan; 81(1):49-53. PubMed ID: 1619569 [TBL] [Abstract][Full Text] [Related]
2. Changes in platelet response to adenosine 5'-diphosphate caused by verapamil. Walkowiak B; Koziołkiewicz W; Michalec L; Pawłowska Z; Krzesłowska J; Cierniewski CS Pol J Pharmacol; 1996; 48(3):303-5. PubMed ID: 9112667 [TBL] [Abstract][Full Text] [Related]
3. Effects of diltiazem and verapamil on ADP-induced rabbit platelet shape change and aggregation. Dehpour AR; Samadian T; Akhavan MM; Meysamee F; Delfan A Gen Pharmacol; 1995 Oct; 26(6):1295-9. PubMed ID: 7590122 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of carvedilol, propranolol, and verapamil on in vitro platelet function in healthy volunteers. Gasser JA; Betterridge DJ J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S29-34. PubMed ID: 1721976 [TBL] [Abstract][Full Text] [Related]
5. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets. Johnson GJ; Leis LA; Francis GS Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784 [TBL] [Abstract][Full Text] [Related]
6. Platelet aggregation: its relation with ADP-induced fibrinogen binding to platelets and ADP-related membrane enzyme activities. Legrand C; Dubernard V; Caen J Eur J Biochem; 1984 Aug; 142(3):465-71. PubMed ID: 6088225 [TBL] [Abstract][Full Text] [Related]
7. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of aggregin by calpain. Puri RN; Zhou FX; Bradford H; Hu CJ; Colman RF; Colman RW Arch Biochem Biophys; 1989 Jun; 271(2):346-58. PubMed ID: 2543293 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of human platelet functions by verapamil. Ikeda Y; Kikuchi M; Toyama K; Watanabe K; Ando Y Thromb Haemost; 1981 Apr; 45(2):158-61. PubMed ID: 6789494 [TBL] [Abstract][Full Text] [Related]
9. Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. Di Minno G; Cerbone A; Usberti M; Cianciaruso B; Cortese A; Farace MJ; Martinez J; Murphy S J Lab Clin Med; 1986 Sep; 108(3):246-52. PubMed ID: 3018111 [TBL] [Abstract][Full Text] [Related]
10. Dose-dependent effects of verapamil and nifedipine on in vivo platelet function in normal volunteers. Winther K; Jespersen CM; Rydberg B; Thamsborg G; Hedner T Eur J Clin Pharmacol; 1990; 39(3):291-3. PubMed ID: 2147908 [TBL] [Abstract][Full Text] [Related]
11. [Experimental research on the action of isoptin and alkylenediamine derivatives on the aggregation capacity and the membrane-bound calcium level of thrombocytes]. Mironiuk EP; Manevich EM; Piotrovskiĭ LB; Dumpis MA Farmakol Toksikol; 1987; 50(2):42-6. PubMed ID: 3582633 [TBL] [Abstract][Full Text] [Related]
12. Regulation of platelet aggregation by post-fibrinogen binding events. Insights provided by dithiothreitol-treated platelets. Peerschke EI Thromb Haemost; 1995 May; 73(5):862-7. PubMed ID: 7482417 [TBL] [Abstract][Full Text] [Related]
13. Ionization and surface properties of verapamil and several verapamil analogues. Retzinger GS; Cohen L; Lau SH; Kézdy FJ J Pharm Sci; 1986 Oct; 75(10):976-82. PubMed ID: 3795029 [TBL] [Abstract][Full Text] [Related]
14. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481 [TBL] [Abstract][Full Text] [Related]
15. Halysin, an antiplatelet Arg-Gly-Asp-containing snake venom peptide, as fibrinogen receptor antagonist. Huang TF; Liu CZ; Ouyang CH; Teng CM Biochem Pharmacol; 1991 Aug; 42(6):1209-19. PubMed ID: 1888330 [TBL] [Abstract][Full Text] [Related]
16. Effect of verapamil on platelet surface ultrastructure and calcium content. Djaldetti M; Gilgal R; Fishman P; Zahavi I Acta Haematol; 1988; 79(1):41-3. PubMed ID: 3124459 [TBL] [Abstract][Full Text] [Related]
17. Colloidal gold labelling of fibrinogen receptors in epinephrine- and ADP-activated platelet suspensions. Oliver JA; Albrecht RM Scanning Microsc; 1987 Jun; 1(2):745-56. PubMed ID: 3616571 [TBL] [Abstract][Full Text] [Related]
18. ADP-stimulated fibrinogen binding is necessary for some of the inositol phospholipid changes found in ADP-stimulated platelets. Vickers JD Eur J Biochem; 1993 Aug; 216(1):231-7. PubMed ID: 8396029 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of platelet function of antiarrhythmic drugs, verapamil and disopyramide. Han P; Boatwright C; Ardlie NG Thromb Haemost; 1982 Apr; 47(2):150-3. PubMed ID: 7101234 [TBL] [Abstract][Full Text] [Related]
20. Exposure of platelet fibrinogen receptors by ADP and epinephrine. Bennett JS; Vilaire G J Clin Invest; 1979 Nov; 64(5):1393-401. PubMed ID: 574143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]